|
|
|
|
|
Didanosine
drug data and news
Didanosine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Didanosine | ||
| Brand Names/Synonyms | 2'3'-DIDEOXYINOSINE; 2DI; CCRIS 805; DDI; DIDEOXYINOSINE; Ddi; Ddi, Didanosine; Didanosine; Didanosine [Usan:Ban:Inn]; Dideoxyinosine; Videx; Videx Ec; [Inn-Latin]; [Inn-Spanish] | ||
| Indication | For treatment of Human immunovirus (HIV) infections | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Didanosine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. | ||
| Mechanism Of Action | Didanosine (ddI) is metabolized intracellularly by a series of cellular enzymes to its active moiety, 2,3–dideoxyadenosine-5-triphosphate (ddA-TP), which inhibits HIV DNA polymerase (reverse transcriptase). Didanosine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. | ||
| Didanosine News (When available) |
Oscient Pharmaceuticals Reports Financial Results for Fourth ... 06 Mar 2006 Fringe wins for pharma, but cos seek stronger dose Feb 28, 2006 Gilead Sciences Welcomes Guidance From Nice On Treatment Of ... Feb 22, 2006 Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006 CROI: Low rates of resistance seen in Staccato trial of CD4-guided ... Feb 26, 2006 Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006 CROI: Capsaicin patch helps relieve neuropathy Feb 10, 2006 CROI: Tenofovir and kidney toxicity - low rates seen, but some ... Feb 9, 2006 Barr reports strong quarterly earnings Feb 8, 2006 CROI: AZT, 3TC and FTC achieve good concentrations in the female ... Feb 17, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 CROI: Tenofovir and kidney toxicity - low rates seen, but some ... 09 Feb 2006 Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006 Barr reports strong quarterly earnings Feb 8, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006 Bristol-Myers Squibb and Gilead Announce Data Supporting ... Jan 9, 2006 Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ... Jan 18, 2006 Drug price reduction makes Aids manageable Jan 25, 2006 FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New ... Jan 20, 2006 Increase ribavirin dose for better HCV treatment response in ... Jan 18, 2006 Unaffordable AIDS Drug Prices... Again 11 Dec 2005 New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the ... Dec 9, 2005 AIDS Patients on Tenofovir Must Be Monitored For Renal Failure ... Nov 14, 2005 What’s your problem? Dec 7, 2005 HIV Virus Emerging Drug Resistant In UK, Prompting Fear Of A ... Nov 18, 2005 The overuse of Tamiflu in treating avian flu Dec 2, 2005 Preliminary 24-Week Data Evaluating the Impact of Switching from ... Nov 17, 2005 Switching from twice-daily Combivir to once-daily Truvada in ... Nov 23, 2005 Fat loss may be restored with dietary supplement Nov 14, 2005 Once-daily boosted saquinavir has low blood levels when used with ... Nov 11, 2005 Simplicity is the Key to Survival in the HIV Market where Older ... Nov 15, 2005 Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ... Oct 7, 2005 Reverset Delay Of Phase III Sends Incyte Stock Reeling Sep 28, 2005 Efavirenz may linger for up to eight weeks after treatment stops Sep 27, 2005 First HIV Drug, Glaxo's AZT, Gets Generic US Rivals (Update1) Sep 19, 2005 Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005 Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005 Gilead Reduces Prices for Viread and Truvada in the Developing ... Aug 29, 2005 In this thing together Sep 1, 2005 US men's study finds cumulative NRTI use, but not PIs or NNRTIs ... Aug 24, 2005 Risk of peripheral neuropathy five times higher for common genetic ... Aug 25, 2005 Anti-HIV drugs linked with nerve damage Aug 26, 2005 Acute Bacterial Sinusitis - Levaquin® (levofloxacin) FDA Approved ... Aug 15, 2005 Timeline: AIDS in America Aug 13, 2005 Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity ... Jul 25, 2005 Incyte shares fall on study results Jul 25, 2005 Epidemiology Study Reports New Information on Hypersensitivity ... Jul 26, 2005 Incyte's HIV Drug Reverset in Phase II Trial Shows Potential in ... Jul 27, 2005 Gilead Sciences and Royalty Pharma Announce $525 Million Agreement ... Jul 18, 2005 IAS: New NRTI D-d4FC active in treatment-experienced patients Jul 28, 2005 MSD grants Aspen generic licence Jul 19, 2005 More to come Jul 19, 2005 | ||
| Dosage Forms | CAPSULE (ENTERIC-COATED); POWDER FOR SOLUTION; TABLET | ||
| Drug_Category | Anti-HIV Agents; Antimetabolites; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF02 | ||
| Absorption | Rapidly absorbed (bioavailability = 30-40%) with peak plasma concentrations appearing within 0.5 and 1.5 hrs. | ||
| Interactions | Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated. Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS). Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min). The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known. Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components. Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX. Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12). A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12). Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum. In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX. The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently. In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed. Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum. The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert. Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX. To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX. The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX. | ||
| Toxicity | Side effects include pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia and hepatic dysfunction | ||
| Organisms Affected | Human immunodeficiency virus | ||
| Chemical IUPAC Name | 9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydropurin-6-one | ||
| Chemical Formula | C10H12N4O3 | ||
| Molecular Weight | 236.227 g/mol | ||
| Smiles String | C1CC(OC1CO)N2C=NC3=C2NC=NC3=O | ||
| Melting Point | 160-163 °C | ||
| Water Solubility | 15.8 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | -1.24 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Rapidly metabolized intracellularly to its active moiety, hypoxanthine, xanthine and uric acid | ||
| Half Life | 1.5 +/- 0.4 hours | ||
| Protein Binding [%] | low (<5%) | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Didanosine.html http://www.rxlist.com/cgi/generic3/didanosine.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/vid1482.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00240 | ||
| CAS Registry Number | 69655-05-6 | ||
| KEGG Compound ID | C06953 | ||
| PubChem ID | SID:189028 | ||
| PharmGKB ID | PA449301 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2244596 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |